000 03824nam a2200397 i 4500
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
999 _c329541
_d329541
_x1
001 329541
003 ES-MaUEC
005 20230102114421.0
008 201123s2020 si |a o |||| 0|eng d
020 _a9789811581793
024 7 _a10.1007/978-981-15-8179-3
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC267
_b2020 EB
100 _aGanai, Shabir Ahmad
_eautor
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
_9672013
245 1 0 _aHistone Deacetylase Inhibitors in Combinatorial Anticancer Therapy
_cby Shabir Ahmad Ganai
250 _aFirst edition 2020
264 1 _aSingapore
_bSpringer Singapore
_c2020
300 _a1 recurso en línea (XVII, 258 páginas)
_b27 ilustraciones, 13 ilustraciones en color
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
490 0 _aBiomedical and Life Sciences (SpringerNature-11642)
490 0 _aBiomedical and Life Sciences (R0) (SpringerNature-43708)
505 0 _aChapter 1_Epigenetic modifying enzymes. -Chapter 2_Epigenetic modifying enzymes implicated in cancer. -Chapter 3_Classification of histone deacetylases (HDACs). -Chapter 4_Implications of 18 HDAC isoforms in therapeutically monotonous cancers. -Chapter 5_Possible Mechanisms of HDACs in Cancer development -- Chapter 6_Different strategies employed for circumventing cancer resistance (chemo and radio) and mitigating toxicity. -Chapter 7_Limitations of conventional therapeutic regimens in treating cancer. -Chapter 8_Overview of epidrugs with special emphasis on HDAC inhibitors (HDACi) -- Chapter 9_HDAC inhibitors as promising epidrugs for treating cancer. -Chapter 10_ HDAC inhibitors in anticancer monotherapy. -Chapter 11_Distinct groups of histone deacetylase inhibitors (HDACi) based on the structural distinction, HDACs targeted. -Chapter 12_Limited efficacy of HDAC inhibitor-based monotherapy. -Chapter 13_Resistance mechanisms generated by cancer cells against HDACi based monotherapy. -Chapter 14_ Toxicity issue of HDAC inhibitor based monotherapy. -Chapter 15_Combinatorial therapeutic strategies of HDACi. -Chapter 16_Designing Selective HDACi using computational and medicinal chemistry approach. -Chapter 17. Current therapeutic challenges and future directions. .
520 3 _aThis book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity. The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity.. Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.
988 _aSpringer_BiomedLife_dic2020
650 7 _2embne
_aCáncer
_xInvestigación
_9182523
710 2 _aSpringerLink
773 0 _tSpringer Nature eBook
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-15-8179-3
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b02/2021
_dz
_eb
_zSI